Literature DB >> 12825932

Structure-activity relationship comparison of (S)-2beta-substituted 3alpha-(bis[4-fluorophenyl]methoxy)tropanes and (R)-2beta-substituted 3beta-(3,4-dichlorophenyl)tropanes at the dopamine transporter.

Mu-Fa Zou1, Theresa Kopajtic, Jonathan L Katz, Amy Hauck Newman.   

Abstract

Extensive structure-activity relationships at the dopamine transporter (DAT) have been developed around two classes of tropane-based ligands. Opposing stereoselectivity and divergent structural requirements for optimal DAT binding suggest that these tropane-based DAT inhibitors may not access identical binding domains. To further investigate this hypothesis, a series of (S)-2beta-carboalkoxy-3alpha-(bis[4-fluorophenyl]methoxy)tropanes (11a-f, 13-16) and their identically (R)-2beta-substituted 3beta-(3,4-dichlorophenyl)tropanes (3, 5a-d) were prepared and evaluated for binding at the DAT and for inhibition of [(3)H]dopamine uptake in rat brain. These studies showed that most of the identically 2-carboalkoxy-substituted analogues, within the two classes of compounds, bind with high affinity to DAT (K(i) = 5.5-100 nM), albeit with opposite stereochemistry. However, the larger azido- (15) and isothiocyanato- (16) (S)-2beta-carbophenylethoxy-3alpha-(bis[4-fluorophenyl]methoxy)tropanes demonstrated a significant decrease in DAT binding potency (IC(50) = 210 and 537 nM, respectively), suggesting that the DAT does not tolerate 2-position steric bulk in the benztropine class, as it does with the 2-substituted 3-aryltropanes. In addition, binding affinities at the serotonin transporter, norepinephrine transporter, and muscarinic receptors were evaluated and compared for compounds 2, 3, 11a-e, and 13. Together, the binding profiles across these systems demonstrated significant differences between these two classes of tropane-based ligands, which may be exploited toward the discovery of a cocaine-abuse pharmacotherapeutic.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825932     DOI: 10.1021/jm0300375

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic.

Authors:  Hai-Ying Zhang; Guo-Hua Bi; Hong-Ju Yang; Yi He; Gilbert Xue; Jiajing Cao; Gianluigi Tanda; Eliot L Gardner; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropsychopharmacology       Date:  2017-03-07       Impact factor: 7.853

2.  Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders.

Authors:  Mu-Fa Zou; Jianjing Cao; Ara M Abramyan; Theresa Kopajtic; Claudio Zanettini; Daryl A Guthrie; Rana Rais; Barbara S Slusher; Lei Shi; Claus J Loland; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-12-11       Impact factor: 7.446

3.  Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.

Authors:  David J Lapinsky; Ranganadh Velagaleti; Nageswari Yarravarapu; Yi Liu; Yurong Huang; Christopher K Surratt; John R Lever; James D Foster; Rejwi Acharya; Roxanne A Vaughan; Howard M Deutsch
Journal:  Bioorg Med Chem       Date:  2010-11-04       Impact factor: 3.641

Review 4.  Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.

Authors:  Maarten E A Reith; Bruce E Blough; Weimin C Hong; Kymry T Jones; Kyle C Schmitt; Michael H Baumann; John S Partilla; Richard B Rothman; Jonathan L Katz
Journal:  Drug Alcohol Depend       Date:  2014-12-18       Impact factor: 4.492

5.  A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.

Authors:  David J Lapinsky; Shaili Aggarwal; Yurong Huang; Christopher K Surratt; John R Lever; James D Foster; Roxanne A Vaughan
Journal:  Bioorg Med Chem       Date:  2009-05-03       Impact factor: 3.641

Review 6.  Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction.

Authors:  Richard B Rothman; Michael H Baumann; Thomas E Prisinzano; Amy Hauck Newman
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

7.  Comparative structure-activity relationships of benztropine analogues at the dopamine transporter and histamine H(1) receptors.

Authors:  Santosh S Kulkarni; Theresa A Kopajtic; Jonathan L Katz; Amy Hauck Newman
Journal:  Bioorg Med Chem       Date:  2006-02-03       Impact factor: 3.641

8.  The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.

Authors:  Peter C Meltzer; Olga Kryatova; Duy-Phong Pham-Huu; Patrick Donovan; Aaron Janowsky
Journal:  Bioorg Med Chem       Date:  2007-11-06       Impact factor: 3.641

9.  New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders.

Authors:  Amy Hauck Newman; Therese Ku; Chloe J Jordan; Alessandro Bonifazi; Zheng-Xiong Xi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2021-01-06       Impact factor: 16.459

10.  Novel Azido-Iodo Photoaffinity Ligands for the Human Serotonin Transporter Based on the Selective Serotonin Reuptake Inhibitor (S)-Citalopram.

Authors:  Vivek Kumar; Nageswari Yarravarapu; David J Lapinsky; Danielle Perley; Bruce Felts; Michael J Tomlinson; Roxanne A Vaughan; L Keith Henry; John R Lever; Amy Hauck Newman
Journal:  J Med Chem       Date:  2015-07-08       Impact factor: 7.446

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.